home





























 

















 





















hrsa

participating institutions:
Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital



NEWS AND NEW DEVELOPMENTS



Therapy of Efavirenz Plus Indinavir in Patients with Extensive Prior Nucleoside Reverse Transcriptase Inhibitor Experience: A Randomized, Double-Blind, Placebo Controlled Trial [Haas DW, et al. JID 2001;183:392]: This is a clinical trial comparing EFV plus IDV (1000 mg q8h) versus IDV (800 mg q8h) alone in 327 NRTI-experienced patients. The study drugs were combined with NRTIs, participants had a mean duration of prior NRTI treatment of 2.8 years, and baseline VL levels were >10,000 c/mL. Analysis at 24 weeks showed that the number with VL <400 c/mL was 68% in the EFV/IDV group compared to 52.4% in the group receiving IDV alone (p = 0.004). These results were sustained to 48 weeks.
Comment: These results are similar to those achieved in DuPont 006 with efavirenz versus indinavir, each with AZT plus 3TC, in treatment-naïve patients. Thus, the major question concerns the need for two new classes in patients with virologic failure because of extensive NRTI exposure.
posted 3/8/2001





Copyright © 2001-2002. The National AIDS Education and Training Centers Program on behalf of its AETC National Resource Center. All rights reserved.

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.